<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092338</url>
  </required_header>
  <id_info>
    <org_study_id>09-007332</org_study_id>
    <secondary_id>R01AT005531</secondary_id>
    <nct_id>NCT01092338</nct_id>
  </id_info>
  <brief_title>Vitamin D Dose Finding Study</brief_title>
  <official_title>Safe and Effective Vitamin D Supplementation in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimal vitamin D (vit D) concentration and metabolism are essential for normal immune
      function, growth, muscle, bone, and inflammatory status in children, adolescents and adults
      with HIV/AIDS. The impact of vit D supplementation will be evaluated for safety and efficacy
      using clinically important outcomes, and this will overcome the critical barrier for use of
      vit D supplementation in research and clinical care. Inexpensive and easy to administer, vit
      D supplementation may prove to be an effective and feasible treatment for symptoms and
      prevention of side effects for people of all ages living with HIV/AIDS in the US and around
      the world.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The key role of vitamin D (vit D) in maintaining optimal bone health has long been
      recognized, but its role in modulating the innate immune response and inflammatory reaction
      has only recently come under active investigation. As such, vit D is an increasingly
      frequently chosen and prescribed high dose dietary supplement,because it is thought to
      improve immune and inflammatory status in healthy people of all ages, and in those with
      chronic diseases including HIV/AIDS. Vit D also has calciotrophic functions essential for
      bone health, and poor vit D status contributes to the osteopenia/osteoporosis associated with
      antiretroviral therapy (ART). Vit D may improve insulin/glucose/lipid metabolism, blood
      pressure and risk of some cancers, all of which may complicate HIV/AIDS and its treatments.
      Poor vit D status is common in patients with HIV/AIDS of all ages and factors such as age,
      skin pigment, lactose intolerance and sun exposure alter the risks for vit D deficiency. In
      the multicenter U.S. REACH study of adolescents (72% African American), with and without HIV,
      showed that 87% had low serum 25D concentrations (&lt;15 ng/mL), compared to 34% in a recent
      sample of healthy African American children from Philadelphia. Young African Americans are
      disproportionately affected by HIV infection in the US (~ 55% among persons with HIV aged 13
      to 24 years are African American), and are also at high risk for vit D deficiency. Vit D
      therapy has great promise to improve major medical conditions and the quality of life for our
      patients with HIV/AIDS, yet the potential role of vit D in the treatment of HIV/AIDS has not
      been formally tested. Well-designed randomized trials are urgently needed to determine vit D
      supplementation safety and efficacy.

      The investigators propose a two-phase study to establish safety and efficacy of high dose vit
      D supplementation in children and adults with HIV/AIDS. In Study Phase I, the safety and
      efficacy of two oral vit D3 doses (4000 and 7000 IU/d) are determined over 12 weeks in 44
      subjects ages 5.0 to 24.9 y. The key safety measure is concurrently elevated serum calcium
      and 25D concentrations. Efficacy is evaluated by serum 25D concentration and cathelicidin
      (innate immune, antimicrobial protein) mRNA expression. Study Phase II is a 12 month, double
      blind, randomized, placebo controlled supplementation study (n=52). Key outcomes include
      safety and longterm 25D concentration within the goal range (32 to 160 ng/mL), improved
      cathelicidin mRNA expression, and measures of bone, muscle, inflammation, growth and body
      composition status, and HIV/AIDS disease severity. Based on the evidence and promise, vit D
      clearly deserves to be among the first nutrients evaluated in the National Center for
      Complimentary and Alternative Medicine (NCCAM) HIV research program.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determined by incidence of elevated serum calcium (above age specific range) associated with elevated serum 25D concentrations (&gt;160ng/ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of the Two Doses (4000 and 7000 IU/d)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Daily D3 supplementation will result in 25D &gt;= to 32/ng/ml</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>4000IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm take a daily dose of 4000IU of Vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7000IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol (Vit D3)</intervention_name>
    <description>To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.</description>
    <arm_group_label>4000IU</arm_group_label>
    <arm_group_label>7000IU</arm_group_label>
    <other_name>Carlson D Drops: The D Drop Company</other_name>
    <other_name>Nutraceutical Life Sciences Vitamin D3 2000 IU capsules: Vitacost</other_name>
    <other_name>NOW Foods 5000 IU softgels: Now Health Group, Inc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV seropositive diagnosed with standard techniques

          2. Age for perinatally-acquired HIV/AIDS Group (PA subjects): 5.0 to 24.9 y

          3. Age for non-perinatally-acquired HIV/AIDS Group (non-PA subjects): 15.0 to 24.9 y

          4. In usual state of good health (no hospitalizations, emergency room or unscheduled
             acute illness visits for 2 weeks prior)

          5. Subject and/or family commitment to the 3-month study

        Exclusion Criteria:

          1. Other chronic health conditions that may affect growth, dietary intake, and/or
             nutritional status

          2. Pregnancy

          3. Participation in another HIV intervention study with impact on 25D serum
             concentrations

          4. Use of vit D supplementation (subjects willing to discontinue supplementation will
             become eligible after a 2-month washout period)

          5. Baseline elevated serum calcium concentration

          6. Non-English speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Stallings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Groleau V, Herold RA, Schall JI, Wagner JL, Dougherty KA, Zemel BS, Rutstein RM, Stallings VA. Blood lead concentration is not altered by high-dose vitamin D supplementation in children and young adults with HIV. J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):316-9. doi: 10.1097/MPG.0b013e3182758c4a.</citation>
    <PMID>23059649</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <results_first_submitted>January 7, 2013</results_first_submitted>
  <results_first_submitted_qc>August 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 18, 2013</results_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Acquired Immune Deficiency Syndrome</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>HIV</keyword>
  <keyword>Complementary therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Study started enrollment in 01/2010 and completed in 01/2011. A total of 44 subjects were enrolled including 19 with perinatally-acquired HIV/AIDS (PA) and 25 with behaviorally-acquired HIV/AIDS (BA).</recruitment_details>
      <pre_assignment_details>Subjects taking a vitamin D supplement or multi-vitamin were eligible if they were willing to discontinue supplementation after a minimum of a 2 month washout period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4000IU/d of Vitamin D3</title>
        </group>
        <group group_id="P2">
          <title>7000IU/d Vitamin D3</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4000IU/d of Vitamin D3</title>
        </group>
        <group group_id="B2">
          <title>7000IU/d Vitamin D3</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.4" spread="4.5"/>
                    <measurement group_id="B2" value="19.1" spread="5.0"/>
                    <measurement group_id="B3" value="18.7" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety</title>
        <description>Determined by incidence of elevated serum calcium (above age specific range) associated with elevated serum 25D concentrations (&gt;160ng/ml).</description>
        <time_frame>12 weeks</time_frame>
        <population>Number of subjects with elevated serum calcium (above age specific range) associated with elevated serum 25D concentrations (&gt;160ng/ml)</population>
        <group_list>
          <group group_id="O1">
            <title>4000IU/d of Vitamin D3</title>
          </group>
          <group group_id="O2">
            <title>7000IU/d Vitamin D3</title>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Determined by incidence of elevated serum calcium (above age specific range) associated with elevated serum 25D concentrations (&gt;160ng/ml).</description>
          <population>Number of subjects with elevated serum calcium (above age specific range) associated with elevated serum 25D concentrations (&gt;160ng/ml)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of the Two Doses (4000 and 7000 IU/d)</title>
        <description>Daily D3 supplementation will result in 25D &gt;= to 32/ng/ml</description>
        <time_frame>12 weeks</time_frame>
        <population>Number of subjects with serum 25D concentration levels &gt;= 32 ng/ml after 12 weeks of supplementation.</population>
        <group_list>
          <group group_id="O1">
            <title>4000IU/d of Vitamin D3</title>
          </group>
          <group group_id="O2">
            <title>7000IU/d Vitamin D3</title>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of the Two Doses (4000 and 7000 IU/d)</title>
          <description>Daily D3 supplementation will result in 25D &gt;= to 32/ng/ml</description>
          <population>Number of subjects with serum 25D concentration levels &gt;= 32 ng/ml after 12 weeks of supplementation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>4000IU/d of Vitamin D3</title>
        </group>
        <group group_id="E2">
          <title>7000IU/d Vitamin D3</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cough/Cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Virginia Stallings</name_or_title>
      <organization>Children's Hospital of Philadephia</organization>
      <phone>215-590-1664</phone>
      <email>stallingsv@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

